Cargando…

Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study

BACKGROUND: Fibroblast growth factor 23 (FGF23), a phosphate-regulating hormone that increases early in the course of chronic kidney disease (CKD), is associated with disease progression in patients with established CKD. Here we aimed to investigate the association between plasma FGF23 and new-onset...

Descripción completa

Detalles Bibliográficos
Autores principales: De Jong, Maarten A, Eisenga, Michele F, van Ballegooijen, Adriana J, Beulens, Joline W J, Vervloet, Marc G, Navis, Gerjan, Gansevoort, Ron T, Bakker, Stephan J L, De Borst, Martin H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771975/
https://www.ncbi.nlm.nih.gov/pubmed/32124925
http://dx.doi.org/10.1093/ndt/gfz266
_version_ 1783629781056618496
author De Jong, Maarten A
Eisenga, Michele F
van Ballegooijen, Adriana J
Beulens, Joline W J
Vervloet, Marc G
Navis, Gerjan
Gansevoort, Ron T
Bakker, Stephan J L
De Borst, Martin H
author_facet De Jong, Maarten A
Eisenga, Michele F
van Ballegooijen, Adriana J
Beulens, Joline W J
Vervloet, Marc G
Navis, Gerjan
Gansevoort, Ron T
Bakker, Stephan J L
De Borst, Martin H
author_sort De Jong, Maarten A
collection PubMed
description BACKGROUND: Fibroblast growth factor 23 (FGF23), a phosphate-regulating hormone that increases early in the course of chronic kidney disease (CKD), is associated with disease progression in patients with established CKD. Here we aimed to investigate the association between plasma FGF23 and new-onset CKD in the general population. METHODS: We included 5253 individuals without CKD who participated in the Prevention of Renal and Vascular Endstage Disease study, a prospective, population-based cohort. Multi-variable Cox regression was used to study the association of plasma C-terminal FGF23 with new-onset CKD, defined as a combined endpoint of estimated glomerular filtration rate (eGFR) <60 mL/min/ 1.73 m(2), urinary 24-h albumin excretion (UAE) >30 mg/24 h or both, or with all-cause mortality. RESULTS: The median baseline FGF23 was 68 [interquartile range (IQR) 56–85] RU/mL, eGFR was 95 ± 13 mL/min/1.73 m(2) and UAE was 7.8 (IQR 5.8–11.5)  mg/24 h. After follow-up of 7.5 (IQR 7.2–8.0)  years, 586 participants developed CKD and 214 participants died. A higher FGF23 level was associated with new-onset CKD, independent of risk factors for kidney disease and parameters of bone and mineral homoeostasis {fully adjusted hazard ratio (HR) 1.25 [95% confidence interval (CI) 1.10–1.44] per doubling of FGF23; P = 0.001}. In secondary analyses, FGF23 was independently associated with new-onset eGFR <60 mL/min/1.73 m(2) [adjusted HR 1.28 (95% CI 1.00–1.62); P = 0.048] or with UAE >30 mg/24 h [adjusted HR 1.24 (95% CI 1.06–1.45); P = 0.01] individually. A higher FGF23 level was also associated with an increased risk of all-cause mortality [fully adjusted HR 1.30 (95% CI 1.03–1.63); P = 0.03]. CONCLUSIONS: High FGF23 levels are associated with an increased risk of new-onset CKD and all-cause mortality in this prospective population-based cohort, independent of established CKD risk factors.
format Online
Article
Text
id pubmed-7771975
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77719752021-01-05 Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study De Jong, Maarten A Eisenga, Michele F van Ballegooijen, Adriana J Beulens, Joline W J Vervloet, Marc G Navis, Gerjan Gansevoort, Ron T Bakker, Stephan J L De Borst, Martin H Nephrol Dial Transplant ORIGINAL ARTICLES BACKGROUND: Fibroblast growth factor 23 (FGF23), a phosphate-regulating hormone that increases early in the course of chronic kidney disease (CKD), is associated with disease progression in patients with established CKD. Here we aimed to investigate the association between plasma FGF23 and new-onset CKD in the general population. METHODS: We included 5253 individuals without CKD who participated in the Prevention of Renal and Vascular Endstage Disease study, a prospective, population-based cohort. Multi-variable Cox regression was used to study the association of plasma C-terminal FGF23 with new-onset CKD, defined as a combined endpoint of estimated glomerular filtration rate (eGFR) <60 mL/min/ 1.73 m(2), urinary 24-h albumin excretion (UAE) >30 mg/24 h or both, or with all-cause mortality. RESULTS: The median baseline FGF23 was 68 [interquartile range (IQR) 56–85] RU/mL, eGFR was 95 ± 13 mL/min/1.73 m(2) and UAE was 7.8 (IQR 5.8–11.5)  mg/24 h. After follow-up of 7.5 (IQR 7.2–8.0)  years, 586 participants developed CKD and 214 participants died. A higher FGF23 level was associated with new-onset CKD, independent of risk factors for kidney disease and parameters of bone and mineral homoeostasis {fully adjusted hazard ratio (HR) 1.25 [95% confidence interval (CI) 1.10–1.44] per doubling of FGF23; P = 0.001}. In secondary analyses, FGF23 was independently associated with new-onset eGFR <60 mL/min/1.73 m(2) [adjusted HR 1.28 (95% CI 1.00–1.62); P = 0.048] or with UAE >30 mg/24 h [adjusted HR 1.24 (95% CI 1.06–1.45); P = 0.01] individually. A higher FGF23 level was also associated with an increased risk of all-cause mortality [fully adjusted HR 1.30 (95% CI 1.03–1.63); P = 0.03]. CONCLUSIONS: High FGF23 levels are associated with an increased risk of new-onset CKD and all-cause mortality in this prospective population-based cohort, independent of established CKD risk factors. Oxford University Press 2020-03-03 /pmc/articles/PMC7771975/ /pubmed/32124925 http://dx.doi.org/10.1093/ndt/gfz266 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle ORIGINAL ARTICLES
De Jong, Maarten A
Eisenga, Michele F
van Ballegooijen, Adriana J
Beulens, Joline W J
Vervloet, Marc G
Navis, Gerjan
Gansevoort, Ron T
Bakker, Stephan J L
De Borst, Martin H
Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study
title Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study
title_full Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study
title_fullStr Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study
title_full_unstemmed Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study
title_short Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study
title_sort fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the prevention of renal and vascular endstage disease (prevend) study
topic ORIGINAL ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771975/
https://www.ncbi.nlm.nih.gov/pubmed/32124925
http://dx.doi.org/10.1093/ndt/gfz266
work_keys_str_mv AT dejongmaartena fibroblastgrowthfactor23andnewonsetchronickidneydiseaseinthegeneralpopulationthepreventionofrenalandvascularendstagediseaseprevendstudy
AT eisengamichelef fibroblastgrowthfactor23andnewonsetchronickidneydiseaseinthegeneralpopulationthepreventionofrenalandvascularendstagediseaseprevendstudy
AT vanballegooijenadrianaj fibroblastgrowthfactor23andnewonsetchronickidneydiseaseinthegeneralpopulationthepreventionofrenalandvascularendstagediseaseprevendstudy
AT beulensjolinewj fibroblastgrowthfactor23andnewonsetchronickidneydiseaseinthegeneralpopulationthepreventionofrenalandvascularendstagediseaseprevendstudy
AT vervloetmarcg fibroblastgrowthfactor23andnewonsetchronickidneydiseaseinthegeneralpopulationthepreventionofrenalandvascularendstagediseaseprevendstudy
AT navisgerjan fibroblastgrowthfactor23andnewonsetchronickidneydiseaseinthegeneralpopulationthepreventionofrenalandvascularendstagediseaseprevendstudy
AT gansevoortront fibroblastgrowthfactor23andnewonsetchronickidneydiseaseinthegeneralpopulationthepreventionofrenalandvascularendstagediseaseprevendstudy
AT bakkerstephanjl fibroblastgrowthfactor23andnewonsetchronickidneydiseaseinthegeneralpopulationthepreventionofrenalandvascularendstagediseaseprevendstudy
AT deborstmartinh fibroblastgrowthfactor23andnewonsetchronickidneydiseaseinthegeneralpopulationthepreventionofrenalandvascularendstagediseaseprevendstudy